Highlights
BrainSight AI Secures $5 Million in Pre-Series A Funding
Deep-tech neuroscience startup BrainSight AI has successfully raised $5 million in a pre-Series A funding round. This round was led by IAN Alpha Fund, with contributions from IvyCap Ventures, Silver Needle, and other current investors. Based in Bengaluru, the company previously attracted $925K from Pfizer and other sources.
The newly acquired funds will be strategically used to:
- Enhance its presence within India, specifically in Tier I and Tier II cities.
- Expand into international markets, including Africa, Southeast Asia, and the US.
- Boost research and development capabilities.
About BrainSight AI
Founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, BrainSight AI is dedicated to improving precision in the diagnosis and treatment planning of neuro-oncological and neuropsychiatric conditions. The platform fuses artificial intelligence with neuroscience to enhance accuracy in neurological and psychiatric investigations, thereby expediting patient outcomes.
Platform Offerings
BrainSight’s product suite comprises:
- Voxelbox – This tool offers clinicians access to an fMRI processing engine and machine learning models.
- Snowdrop – A patient care application designed to ensure adherence to treatment schedules and assist in the creation of patient profiles.
Currently, BrainSight AI reports collaboration with over 40 leading hospitals across India, particularly within neurosurgery and radiology departments, focusing on brain tumour cases. The company plans to extend its solutions to encompass neurological and psychiatric disorders, promoting a comprehensive approach to brain health.
BrainSight AI is dedicated to enhancing the understanding of how brain physiology relates to its functions. By mapping macro-scale neural connections, the platform aims to facilitate precise diagnoses and prognoses of neuro-oncological and neuropsychiatric disorders.
